138 related articles for article (PubMed ID: 27155186)
1. CYP7A1, BAAT and UGT1A1 polymorphisms and susceptibility to anti-tuberculosis drug-induced hepatotoxicity.
Chen R; Wang J; Tang SW; Zhang Y; Lv XZ; Wu SS; Yang ZR; Xia YY; Chen DF; Zhan SY
Int J Tuberc Lung Dis; 2016 Jun; 20(6):812-8. PubMed ID: 27155186
[TBL] [Abstract][Full Text] [Related]
2. Genetic Polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and Susceptibility to Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Chinese Population-Based Prospective Case-Control Study.
Sun Q; Liu HP; Zheng RJ; Wang P; Liu ZB; Sha W; Xiao HP
Clin Drug Investig; 2017 Dec; 37(12):1125-1136. PubMed ID: 28900877
[TBL] [Abstract][Full Text] [Related]
3. Association between NR1I2 polymorphisms and susceptibility to anti-tuberculosis drug-induced hepatotoxicity in an Eastern Chinese Han population: A case-control study.
Yang M; Pan H; Chen H; Liu W; Lu L; He X; Yi H; Tang S
Infect Genet Evol; 2020 Sep; 83():104349. PubMed ID: 32387752
[TBL] [Abstract][Full Text] [Related]
4. The association between BACH1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese cohort.
Zhang H; Qian H; Tao B; Yang M; Gong J; Yi H; Tang S
Infect Genet Evol; 2018 Dec; 66():217-221. PubMed ID: 30316884
[TBL] [Abstract][Full Text] [Related]
5. CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study.
Tang SW; Lv XZ; Zhang Y; Wu SS; Yang ZR; Xia YY; Tu DH; Deng PY; Ma Y; Chen DF; Zhan SY
J Clin Pharm Ther; 2012 Oct; 37(5):588-93. PubMed ID: 22335459
[TBL] [Abstract][Full Text] [Related]
6. A validation study of the UGT1A4 rs2011404 variant and the risk of anti-tuberculosis drug-induced hepatotoxicity in an Eastern Chinese Han population.
Zhu J; Liu W; Zhang M; Lu L; Pan H; He X; Wang N; Yang M; Yi H; Tang S
J Clin Pharm Ther; 2021 Oct; 46(5):1288-1294. PubMed ID: 34046917
[TBL] [Abstract][Full Text] [Related]
7. NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population.
Lv X; Tang S; Xia Y; Zhang Y; Wu S; Yang Z; Li X; Tu D; Chen Y; Deng P; Ma Y; Chen D; Chen R; Zhan S
Ann Hepatol; 2012; 11(5):700-7. PubMed ID: 22947533
[TBL] [Abstract][Full Text] [Related]
8. Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population.
Wang Y; Xiang X; Wu SQ; Chen G; Zhang MM; Wang MG; Wang FJ; Sandford AJ; He JQ
Infect Genet Evol; 2017 Jul; 51():198-202. PubMed ID: 28389387
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-4 and interleukin-10 polymorphisms and antituberculosis drug-induced hepatotoxicity in Chinese population.
Wang J; Chen R; Tang S; Lv X; Wu S; Zhang Y; Yang Z; Xia Y; Chen D; Zhan S
J Clin Pharm Ther; 2015 Apr; 40(2):186-91. PubMed ID: 25308608
[TBL] [Abstract][Full Text] [Related]
10. Relevance of NAT2 genotype to anti-tuberculosis drug-induced hepatotoxicity in a Chinese Han population.
Lu L; Tao B; Wei H; Chen H; He X; Pan H; Yang M; Yi H; Tang S
J Gene Med; 2019 Jun; 21(6):e3096. PubMed ID: 31066138
[TBL] [Abstract][Full Text] [Related]
11. Association between TXNRD1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a prospective study.
Ji GY; Wang Y; Wu SQ; Liu QQ; Wu JC; Zhang MM; Sandford AJ; He JQ
Genet Mol Res; 2016 Sep; 15(3):. PubMed ID: 27706680
[TBL] [Abstract][Full Text] [Related]
12. UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications.
Chang JC; Liu EH; Lee CN; Lin YC; Yu MC; Bai KJ; Chen HY
Int J Tuberc Lung Dis; 2012; 16(3):376-8. PubMed ID: 22230213
[TBL] [Abstract][Full Text] [Related]
13. rs1800796 of the IL6 gene is associated with increased risk for anti-tuberculosis drug-induced hepatotoxicity in Chinese Han children.
Li Y; Tang H; Qi H; Shen C; Sun L; Li J; Xu F; Jiao W; Yang X; Shen A
Tuberculosis (Edinb); 2018 Jul; 111():71-77. PubMed ID: 30029918
[TBL] [Abstract][Full Text] [Related]
14. Analysis of silent information regulator 1 (SIRT1) gene polymorphisms in antituberculosis- drug-induced hepatotoxicity in a prospective cohort study.
Wang Y; Yan XY; Wu JC; Ji GY; Wu SQ; Huang WW; Chen G; Sandford AJ; He JQ
Int J Clin Pharmacol Ther; 2016 Oct; 54(10):775-81. PubMed ID: 26952036
[TBL] [Abstract][Full Text] [Related]
15. Possible association of HMOX1 and NQO1 polymorphisms with anti-tuberculosis drug-induced liver injury: A matched case-control study.
Yang M; Zhang H; Tao B; Pan H; Lu L; Yi H; Tang S
J Clin Pharm Ther; 2019 Aug; 44(4):534-542. PubMed ID: 30776144
[TBL] [Abstract][Full Text] [Related]
16. Association of
Wang N; Chen X; Hao Z; Yi H; Tang S
Xenobiotica; 2022 May; 52(5):527-533. PubMed ID: 35735268
[TBL] [Abstract][Full Text] [Related]
17. Genetic Polymorphisms of Glutathione S-Transferase P1 (GSTP1) and the Incidence of Anti-Tuberculosis Drug-Induced Hepatotoxicity.
Wu S; Wang YJ; Tang X; Wang Y; Wu J; Ji G; Zhang M; Chen G; Liu Q; Sandford AJ; He JQ
PLoS One; 2016; 11(6):e0157478. PubMed ID: 27281183
[TBL] [Abstract][Full Text] [Related]
18. Analysis of IL-6, STAT3 and HSPA1L gene polymorphisms in anti-tuberculosis drug-induced hepatitis in a nested case-control study.
Wang J; Chen R; Tang S; Lv X; Wu S; Zhang Y; Xia Y; Gao P; Tu D; Chen D; Zhan S
PLoS One; 2015; 10(3):e0118862. PubMed ID: 25789467
[TBL] [Abstract][Full Text] [Related]
19. Collagen type XVIII alpha 1 chain (COL18A1) variants affect the risk of anti-tuberculosis drug-induced hepatotoxicity: A prospective study.
Cheng Y; Jiao L; Li W; Wang J; Lin Z; Lai H; Ying B
J Clin Lab Anal; 2021 Feb; 35(2):e23630. PubMed ID: 33296124
[TBL] [Abstract][Full Text] [Related]
20. Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients.
Nanashima K; Mawatari T; Tahara N; Higuchi N; Nakaura A; Inamine T; Kondo S; Yanagihara K; Fukushima K; Suyama N; Kohno S; Tsukamoto K
Tuberculosis (Edinb); 2012 May; 92(3):253-9. PubMed ID: 22341855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
